Synthesis, antimicrobial activity, drug likeness and in silico toxicity study of some novel Triazole derivatives
Abstract
A series of novel 1,2,4- Triazole was synthesized and investigated for antimicrobial activity. The structures of all synthesized compounds were confirmed by means of elemental analysis, IR, 1H NMR, and LCMS. All compounds were evaluated for antimicrobial activity cup plate method against S. aureus, B. anthracis, P. aeruginosa, E. coli, C. albicans and A. niger. Compounds 3a, 3b and 3e showed mild to moderate activity, whereas compound 3c and 3d showed significant activity against gram positive bacteria. In case of antifungal activity, compounds 3b and 3c showed mild to moderate activity against the fungal strains as compared with fluconazole. The predicted results showed that all of the compounds (3a-3f) may not have overall toxicity and any other kind of toxicity and showed great % absorbance ranging from 93.25 to 94.22 %.
Keywords:
1,2,4- Triazole, antimicrobial activity, in silico toxicity, drug likeness, % absorbanceDOI
https://doi.org/10.25004/IJPSDR.2021.130114References
Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. Pharmacy and therapeutics. 2015; 40(4):277.
Busch MP, Wright DJ, Custer B, Tobler LH, Stramer SL, Kleinman SH, Prince HE, Bianco C, Foster G, Petersen LR, Nemo G. West Nile virus infections projected from blood donor screening data, United States, 2003. Emerging infectious diseases. 2006; 12(3):395.
Kniesner TJ, Sullivan R. The forgotten numbers: A closer look at COVID-19 non-fatal valuations. Journal of Risk and Uncertainty. 2020; 61(2):155-76.
Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H, Centers for Disease Control and Prevention (CDC), National Institutes of Health, HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. MMWR Recomm Rep. 2009; 58(4):1-207.
Tauxe RV. Emerging foodborne diseases: an evolving public health challenge. Emerging infectious diseases. 1997; 3(4):425.
Manjunath SH, Jones AH, Gabhane M. Local drug delivery systems in periodontal treatment: A review. Sch J Dent Sci. 2017; 4:440-3.
Whittle BJ. Gastrointestinal effects of nonsteroidal anti‐inflammatory drugs. Fundamental & clinical pharmacology. 2003; 17(3):301-13.
Gollnick HP, Krautheim A. Topical treatment in acne: current status and future aspects. Dermatology. 2003; 206(1):29-36.
Weikel Jr JH, Bartek MJ. Toxicologic properties and metabolic fate of haloprogin, an antifungal agent. Toxicology and applied pharmacology. 1972; 22(3):375-86.
Velpandian T. Intraocular penetration of antimicrobial agents in ophthalmic infections and drug delivery strategies. Expert opinion on drug delivery. 2009; 6(3):255-70.
Kaye ET. Topical antibacterial agents. Infectious disease clinics of North America. 2000; 14(2):321-39.
Kumari S, Harjai K, Chhibber S. Bacteriophage versus antimicrobial agents for the treatment of murine burn wound infection caused by Klebsiella pneumoniae B5055. Journal of Medical Microbiology. 2011; 60(2):205-10.
Walsh C. Molecular mechanisms that confer antibacterial drug resistance. Nature. 2000; 406(6797):775-81.
White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clinical microbiology reviews. 1998; 11(2):382-402.
Goldstein AL, McCusker JH. Three new dominant drug resistance cassettes for gene disruption in Saccharomyces cerevisiae. Yeast. 1999; 15(14):1541-53.
Sekyere JO, Asante J. Emerging mechanisms of antimicrobial resistance in bacteria and fungi: advances in the era of genomics. Future microbiology. 2018; 13(2):241-62.
Mitscher LA, Pillai SP, Gentry EJ, Shankel DM. Multiple drug resistance. Medicinal research reviews. 1999; 19(6):477-96.
Roca I, Akova M, Baquero F, Carlet J, Cavaleri M, Coenen S, Cohen J, Findlay D, Gyssens I, Heure OE, Kahlmeter G. The global threat of antimicrobial resistance: science for intervention. New microbes and new infections. 2015; 6:22-9.
Ferri M, Ranucci E, Romagnoli P, Giaccone V. Antimicrobial resistance: a global emerging threat to public health systems. Critical reviews in food science and nutrition. 2017; 57(13):2857-76.
Hong HL, Hong SB, Ko GB, Huh JW, Sung H, Do KH, Kim SH, Lee SO, Kim MN, Jeong JY, Lim CM. Viral infection is not uncommon in adult patients with severe hospital-acquired pneumonia. PloS one. 2014; 9(4):e95865.
Gupta A. Hospital-acquired infections in the neonatal intensive care unit-Klebsiella pneumoniae. In Seminars in perinatology 2002; 26(5):340-345.
Milovanovic T, Dumic I, Veličkovic J, Lalosevic MS, Nikolic V, Palibrk I. Epidemiology and risk factors for multi-drug resistant hospital-acquired urinary tract infection in patients with liver cirrhosis: single center experience in Serbia. BMC infectious diseases. 2019; 19(1):141.
Piotrowska DG, Balzarini J, Głowacka IE. Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1, 2, 3-triazole linker. European Journal of Medicinal Chemistry. 2012; 47:501-9.
Witkowski JT, Robins RK, Khare GP, Sidwell RW. Synthesis and antiviral activity of 1,2,4-triazole-3-thiocarboxamide and 1,2,4-triazole-3-carboxamidine ribonucleosides. Journal of Medicinal Chemistry. 1973, 16(8):935-937.
Rbaa M, Abousalem AS, Rouifi Z, Benkaddour R, Dohare P, Lakhrissi M, Warad I, Lakhrissi B, Zarrouk A. Synthesis, antibacterial study and corrosion inhibition potential of newly synthesis oxathiolan and triazole derivatives of 8-hydroxyquinoline: Experimental and theoretical approach. Surfaces and Interfaces. 2020; 19:100468.
Faidallah HM, Girgis AS, Tiwari AD, Honkanadavar HH, Thomas SJ, Samir A, Kalmouch A, Alamry KA, Khan KA, Ibrahim TS, AL-Mahmoudy AM. Synthesis, antibacterial properties and 2D-QSAR studies of quinolone-triazole conjugates. European journal of medicinal chemistry. 2018; 143:1524-34.
El-Sayed R. Synthesis, antibacterial and surface activity of 1,2,4-triazole derivatives. Grasas y aceites. 2006; 57(2):180-8.
Tang R, Jin L, Mou C, Yin J, Bai S, Hu D, Wu J, Yang S, Song B. Synthesis, antifungal and antibacterial activity for novel amide derivatives containing a triazole moiety. Chemistry Central Journal. 2013; 7(1):30.
Yurttaş L, CantŘrk Z. The synthesis, antifungal and apoptotic effects of triazole-oxadiazoles against Candida species. European Journal of Medicinal Chemistry. 2018; 144:255-61.
Sangshetti JN, Lokwani DK, Sarkate AP, Shinde DB. Synthesis, Antifungal Activity, and Docking Study of Some New 1,2,4‐triazole Analogs. Chemical biology & drug design. 2011; 78(5):800-809.
Menendez C, Gau S, Lherbet C, Rodriguez F, Inard C, Pasca MR, Baltas M. Synthesis and biological activities of triazole derivatives as inhibitors of InhA and antituberculosis agents. European Journal of Medicinal Chemistry. 2011; 46(11):5524-31.
Kumar KK, Seenivasan SP, Kumar V, Das TM. Synthesis of quinoline coupled [1, 2, 3]-triazoles as a promising class of anti-tuberculosis agents. Carbohydrate Research. 2011; 346(14):2084-90.
Almasirad A, Vousooghi N, Tabatabai SA, Kebriaeezadeh A, Shafiee A. Synthesis, Anticonvulsant and Muscle Relaxant Activities of Substituted 1,3,4-oxadiazole, 1,3,4-thiadiazole and 1, 2, 4-triazole. Acta chimica slovenica. 2007; 54(2).
Deng XQ, Song MX, Zheng Y, Quan ZS. Design, synthesis and evaluation of the antidepressant and anticonvulsant activities of triazole-containing quinolinones. European Journal of Medicinal Chemistry. 2014; 73:217-24.
Ayati A, Emami S, Foroumadi A. The importance of triazole scaffold in the development of anticonvulsant agents. European journal of medicinal chemistry. 2016; 109:380-92.
Sari S, Kaynak FB, Dalkara S. Synthesis and anticonvulsant screening of 1,2,4-triazole derivatives. Pharmacological Reports. 2018; 70(6):1116-23.
Deng XQ, Song MX, Zheng Y, Quan ZS. Design, synthesis and evaluation of the antidepressant and anticonvulsant activities of triazole-containing quinolinones. European Journal of Medicinal Chemistry. 2014; 73:217-24.
Radhika C, Venkatesham A, Sarangapani M. Synthesis and antidepressant activity of di substituted-5-aryl-1, 2, 4-triazoles. Medicinal Chemistry Research. 2012; 21(11):3509-13.
Hussein MA, Shaker RM, Ameen MA, Mohammed MF. Synthesis, anti-inflammatory, analgesic, and antibacterial activities of some triazole, triazolothiadiazole, and triazolothiadiazine derivatives. Archives of pharmacal research. 2011; 34(8):1239.
Ahmadi F, Rezayan Ghayahbashi M, Sharifzadeh M, Alipoiur E, Nasser Ostad S, Vosooghi M, Amini M. Synthesis and evaluation of anti-inflammatory and analgesic activities of new 1, 2, 4-triazole derivatives. Medicinal Chemistry. 2015; 11(1):69-76.
El-Sherief HA, Youssif BG, Bukhari SN, Abdelazeem AH, Abdel-Aziz M, Abdel-Rahman HM. Synthesis, anticancer activity and molecular modeling studies of 1,2,4-triazole derivatives as EGFR inhibitors. European Journal of Medicinal Chemistry. 2018; 156:774-89.
Ruddarraju RR, Murugulla AC, Kotla R, Tirumalasetty MC, Wudayagiri R, Donthabakthuni S, Maroju R. Design, synthesis, anticancer activity and docking studies of theophylline containing 1, 2, 3-triazoles with variant amide derivatives. Med Chem Comm. 2017; 8(1):176-83.
Parashar, B, Punjabi, PB, Gupta, GD, Sharma, VK. Synthesis of some novel N-arylhydrazone derivatives of N-phenyl anthranilic acid. International Journal of ChemTech Research, 2009; 1: 1022-1025.
Salgın-Gökşen U, Gökhan-Kelekçi N, Göktaş Ö, Köysal Y, Kılıç E, Işık Ş, Aktay G, Özalp M. 1-Acylthiosemicarbazides, 1,2,4-triazole-5 (4H)-thiones, 1,3,4-thiadiazoles and hydrazones containing 5-methyl-2-benzoxazolinones: synthesis, analgesic-anti-inflammatory and antimicrobial activities. Bioorganic & Medicinal Chemistry. 2007; 15(17):5738-5751.
Mallemula VR, Sanghai NN, Himabindu V, Chakravarthy AK. Synthesis and characterization of antibacterial 2-(pyridin-3-yl)-1H-benzo [d] imidazoles and 2-(pyridin-3-yl)-3H-imidazo [4, 5-b] pyridine derivatives. Research on Chemical Intermediates. 2015; 41(4):2125-38.
http://www.compudrug.com/ (Retrieved on 13/06/2018)
Moorthy NS, Singh RJ, Singh HP, Gupta SD. Synthesis, biological evaluation and in silico metabolic and toxicity prediction of some flavanone derivatives. Chemical and pharmaceutical bulletin. 2006; 54(10):1384-90.
Pallas 3.1.1.2, ADME-Tox software, CompuDrug International Inc., U.S.A., 2000
http://www.molinspiration.com/cgi-bin/properties (Retrived on 1/11/2019)
Zhao YH, Abraham MH, Le J, Hersey A, Luscombe CN, Beck G, Sherborne B, Cooper I. Rate-limited steps of human oral absorption and QSAR studies. Pharmaceutical research. 2002;19(10):1446-57.
Published

